The ozempic vs wegovy question has a simple answer that surprises most people: they are the exact same drug. Both are once-weekly injections of semaglutide, made by the same company, Novo Nordisk. What separates them is the paperwork — and the paperwork matters a lot. Ozempic is FDA-approved for type 2 diabetes with a maximum dose of 2 mg per week. Wegovy is FDA-approved for chronic weight management with a higher maximum dose of 2.4 mg per week. Those two differences drive everything else: who can get a prescription, what insurance will pay, and what you spend each month.
Ozempic vs Wegovy: The Key Difference in One Minute
Semaglutide is a GLP-1 receptor agonist. Per the Cleveland Clinic, drugs in this class copy a gut hormone called GLP-1 — they trigger insulin release, slow how fast your stomach empties, and quiet appetite signals in the brain. The molecule does not know which box it shipped in.
The FDA approval is what splits the two products. Ozempic’s label says it treats type 2 diabetes by lowering blood sugar, and it also carries an approval to reduce the risk of major cardiovascular events in adults with type 2 diabetes and known heart disease. Wegovy’s label says it treats obesity and overweight, alongside a reduced-calorie diet and more physical activity.
That means using Ozempic for weight loss alone is off-label. A licensed clinician can legally prescribe it that way, but insurers almost never pay for it, and the diabetes-focused supply has better uses. If weight is the goal, Wegovy is the semaglutide product built and approved for the job.
Same Molecule, Two Different FDA Approvals
Ozempic came first. The FDA approved it in 2017 for adults with type 2 diabetes, and it quickly became one of the most prescribed diabetes drugs in the country. Weight loss showed up in its trials as a side benefit, not the main event.
Wegovy followed in June 2021, when the FDA approved it as the first new drug for chronic weight management since 2014. The approval covers adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure or type 2 diabetes. The FDA later extended Wegovy to adolescents 12 and older with obesity, and in March 2024 added an approval to cut the risk of heart attack and stroke in adults with heart disease and excess weight.
Why does the label matter if the molecule is identical? Three reasons. Prescribers must match the product to the diagnosis, insurance plans pay based on the approved use, and the two products are dosed differently — which brings us to the numbers.
Dose Schedules Compared: 2 mg vs 2.4 mg
Both drugs start at the same tiny 0.25 mg weekly dose and step up every four weeks so your stomach can adjust. They part ways at the top. Per the Wegovy prescribing information, the full escalation takes about 16 weeks and lands at a 2.4 mg weekly maintenance dose. Ozempic maintenance starts at 0.5 mg and can rise to 1 mg and then a 2 mg maximum, but only as needed for blood sugar control.
| Weeks on the drug | Wegovy weekly dose | Ozempic weekly dose |
|---|---|---|
| Weeks 1–4 | 0.25 mg | 0.25 mg (starter only) |
| Weeks 5–8 | 0.5 mg | 0.5 mg (first maintenance) |
| Weeks 9–12 | 1 mg | 1 mg (if needed) |
| Weeks 13–16 | 1.7 mg | Not available |
| Week 17 onward | 2.4 mg (maintenance) | 2 mg (maximum) |
Two practical notes. Wegovy’s 1.7 mg and 2.4 mg steps simply do not exist on an Ozempic pen, so the two products cannot fully substitute for each other at the high end. And the pens differ: Wegovy ships as single-use pens, one per weekly dose, while an Ozempic pen holds multiple doses. Our semaglutide dosage chart walks through the full titration schedule, week by week, including what to do about missed doses.
Ozempic vs Wegovy Comparison Table
Here is the whole comparison in one place.
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA-approved for | Type 2 diabetes; heart-risk reduction in T2D with heart disease | Chronic weight management (BMI 30+, or 27+ with a condition); heart-risk reduction with heart disease |
| First approved | 2017 | June 2021 |
| Weekly doses | 0.25, 0.5, 1, 2 mg | 0.25, 0.5, 1, 1.7, 2.4 mg |
| Maximum dose | 2 mg | 2.4 mg |
| Weight-loss evidence at label dose | Studied for blood sugar; weight loss secondary | ~14.9% average loss over 68 weeks (STEP 1) |
| Ages approved | Adults | Adults and adolescents 12+ |
| Typical insurance status | Often covered for diabetes | Weight-loss coverage varies; often excluded |
| Cash price without insurance | About $900–$1,100/month via telehealth listings | Roughly $1,349/month list at retail |
Which One Works Better for Weight Loss?
The honest answer: Wegovy has the evidence, because Wegovy’s dose is the one that was tested. In the STEP 1 trial, published in the New England Journal of Medicine, adults without diabetes taking weekly 2.4 mg semaglutide lost an average of 14.9% of their body weight over 68 weeks, versus 2.4% on placebo. Everyone in the trial also followed a reduced-calorie diet and exercise plan.
Ozempic was never put through a large obesity trial at its 2 mg cap, so nobody can quote you an equivalent number. Dose-comparison research points the same direction, though: higher semaglutide doses produced greater average weight loss, which is exactly why Novo Nordisk developed the 2.4 mg dose as a separate product. Results also vary a lot from person to person — averages are not guarantees, and some people respond far more than others.
For context, semaglutide is no longer the ceiling. Tirzepatide, sold as Zepbound for weight management, produced up to 20.9% average weight loss over 72 weeks in the SURMOUNT-1 trial. If you are weighing both molecules, our semaglutide vs tirzepatide guide breaks down the trials, doses, and costs side by side.
Cost and Insurance: Where the Real Gap Shows Up
For most people, the ozempic vs wegovy decision is settled by insurance, not pharmacology. Many commercial plans cover Ozempic when you have a type 2 diabetes diagnosis, usually after a prior authorization. Weight-loss medications sit in a different bucket: plenty of employer plans exclude them completely, which leaves Wegovy uncovered no matter how strong the medical case is.
Medicare adds its own wrinkle. Federal law bars Medicare drug plans from covering medications prescribed only for weight loss. They can cover Ozempic for diabetes, and since 2024 some plans cover Wegovy when it is prescribed to reduce heart-attack and stroke risk in patients with established heart disease.
Paying cash is where sticker shock lives. Wegovy’s list price runs roughly $1,349 per month at a retail pharmacy, and cash-pay Ozempic shows up around $900–$1,100 per month in telehealth listings. Telehealth cash programs sell brand-name Wegovy pens from $199 the first month, then $199–$399 per month by dose, plus membership fees — prices stated to match Novo Nordisk’s own NovoCare direct channel — and our comparison of Wegovy alternatives ranks those options by real total cost.
One warning as you shop: compounded semaglutide, the $99–$299/month copy sold by many telehealth sites, is not FDA-approved, and the FDA has flagged dosing errors and adverse-event reports with compounded GLP-1 drugs. If you are weighing that cheaper route anyway, our rundown of where to get semaglutide online shows which providers name their compounding pharmacies and which hide them.
Side Effects and Safety: Effectively Identical
Because the active drug is the same, the side-effect profile is too. Per the Mayo Clinic, the most common issues are stomach-related: nausea, vomiting, diarrhea, and constipation, especially during the weeks after each dose increase. Most of these fade as your body adjusts, and the slow 16-week ramp-up exists specifically to soften them.
Both products carry the same boxed warning: semaglutide caused thyroid C-cell tumors in rodent studies, so neither drug should be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Both labels also warn about pancreatitis, gallbladder problems, and low blood sugar when combined with insulin or sulfonylureas, and neither should be used during pregnancy.
One rule matters more than the rest: never take Ozempic and Wegovy together. They are the same molecule, so stacking them is a double dose, not a double benefit. The NIDDK also notes that weight regain is common if you stop a GLP-1 medication, so plan for long-term use before you start.
Can You Switch Between Ozempic and Wegovy?
Yes — switching is common, and it usually happens for insurance reasons. Someone covered for Ozempic who loses that coverage may move to Wegovy through a savings program, or the reverse: a patient with type 2 diabetes may switch to Ozempic because that is the version their plan pays for.
A clinician has to manage the change, because the doses do not line up one-to-one above 1 mg. Someone on 2 mg of Ozempic has no exact Wegovy equivalent and typically lands on either 1.7 mg or 2.4 mg based on their doctor’s judgment. Do not attempt a do-it-yourself switch by stretching or combining pens.
The bottom line: Ozempic and Wegovy are one drug wearing two labels. If you have type 2 diabetes, Ozempic is the version built — and usually covered — for you. If weight management is the goal, Wegovy is the FDA-approved path with the trial data behind it, and the 2.4 mg dose that produced that ~14.9% average loss. The molecule is settled science; the smart shopping is all in the coverage and the monthly price.